Additionally, PRMT5 has emerged as a key mediator of AKT’s oncogenic activity through methylation, promoting tumor cell metastasis, and targeting PRMT5 shows promise for cancer therapy (Huang et al., 2022). This evidence concerns the gene PRMT5 and cancer.